Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension

Journal of Cardiology

Volumn 60, Issue 5, 2012, Pages 344-349

  Yao, Atsushi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Combination therapy; Monotherapy; Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMATINIB; LIVER ENZYME; MACITENTAN; PHOSPHODIESTERASE IV INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; RIOCIGUAT; SELEXIPAG; SILDENAFIL; TADALAFIL; TREPROSTINIL;

CARDIOTOXICITY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; HIGH CARDIAC OUTPUT SYNDROME; HUMAN; HYPOXIA; LIVER INJURY; LOW DRUG DOSE; LUNG BLOOD VESSEL; LUNG CAPACITY; LUNG FIBROSIS; MONOTHERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME;

DRUG THERAPY, COMBINATION; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, ENDOTHELIN;

EID: 84868618426     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.08.009     Document Type: Review

References (51)

1. Dresdale D.T., Michtom R.J., Schultz M. Recent studies in primary pulmonary hypertension, including pharmacodynamic observations on pulmonary vascular resistance. Bull N Y Acad Med 1954, 30:195-207.
2. Harris P. Influence of acetylcholine on the pulmonary arterial pressure. Br Heart J 1957, 19:272-278.
3. McLaughlin V.V., Presberg K.W., Doyle R.L., Abman S.H., McCrory D.C., Fortin T., Ahearn G. Prognosis of pulmonary arterial hypertension: Accp evidence-based clinical practice guidelines. Chest 2004, 126:78S-92S.
4. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
5. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., Kimura S., Masaki T., Duguid W.P., Stewart D.J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328:1732-1739.
6. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
7. Rubin L.J., Badesch D.B., Barst R.J., Galie N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
8. Galie N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.L., Barbera J.A., Beghetti M., Corris P., Gaine S., Gibbs J.S., Gomez-Sanchez M.A., Jondeau G., Klepetko W., Opitz C., Peacock A., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2537.
9. McLaughlin V.V., Archer S.L., Badesch D.B., Barst R.J., Farber H.W., Lindner J.R., Mathier M.A., McGoon M.D., Park M.H., Rosenson R.S., Rubin L.J., Tapson V.F., Varga J. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009, 53:1573-1619.
10. Galie N., Palazzini M., Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010, 31:2080-2086.
11. Tuder R.M., Cool C.D., Geraci M.W., Wang J., Abman S.H., Wright L., Badesch D., Voelkel N.F. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999, 159:1925-1932.
12. Geraci M.W., Gao B., Shepherd D.C., Moore M.D., Westcott J.Y., Fagan K.A., Alger L.A., Tuder R.M., Voelkel N.F. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999, 103:1509-1515.
13. Rubin L.J., Mendoza J., Hood M., McGoon M., Barst R., Williams W.B., Diehl J.H., Crow J., Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990, 112:485-491.
14. McLaughlin V.V., Shillington A., Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002, 106:1477-1482.
15. Sitbon O., Humbert M., Nunes H., Parent F., Garcia G., Herve P., Rainisio M., Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002, 40:780-788.
16. Akagi S., Nakamura K., Miyaji K., Ogawa A., Kusano K.F., Ito H., Matsubara H. Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J 2010, 74:2200-2205.
17. Rich S., McLaughlin V.V. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999, 34:1184-1187.
18. Ghofrani H.A., Wiedemann R., Rose F., Schermuly R.T., Olschewski H., Weissmann N., Gunther A., Walmrath D., Seeger W., Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002, 360:895-900.
19. Olschewski H., Simonneau G., Galie N., Higenbottam T., Naeije R., Rubin L.J., Nikkho S., Speich R., Hoeper M.M., Behr J., Winkler J., Sitbon O., Popov W., Ghofrani H.A., Manes A., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329.
20. Saji T., Ozawa Y., Ishikita T., Matsuura H., Matsuo N. Short-term hemodynamic effect of a new oral pgi2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 1996, 78:244-247.
21. Okano Y., Yoshioka T., Shimouchi A., Satoh T., Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997, 349:1365.
22. Bohm F., Pernow J. The importance of endothelin-1 for vascular dysfunction in cardiovascular disease. Cardiovasc Res 2007, 76:8-18.
23. Galie N., Rubin L., Hoeper M., Jansa P., Al-Hiti H., Meyer G., Chiossi E., Kusic-Pajic A., Simonneau G. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (early study): a double-blind, randomised controlled trial. Lancet 2008, 371:2093-2100.
24. Galie N., Olschewski H., Oudiz R.J., Torres F., Frost A., Ghofrani H.A., Badesch D.B., McGoon M.D., McLaughlin V.V., Roecker E.B., Gerber M.J., Dufton C., Wiens B.L., Rubin L.J. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (aries) study 1 and 2. Circulation 2008, 117:3010-3019.
25. Oudiz R.J., Galie N., Olschewski H., Torres F., Frost A., Ghofrani H.A., Badesch D.B., McGoon M.D., McLaughlin V.V., Roecker E.B., Harrison B.C., Despain D., Dufton C., Rubin L.J. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009, 54:1971-1981.
26. Paul G.A., Gibbs J.S., Boobis A.R., Abbas A., Wilkins M.R. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005, 60:107-112.
27. Wrishko R.E., Dingemanse J., Yu A., Darstein C., Phillips D.L., Mitchell M.I. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008, 48:610-618.
28. Galie N., Brundage B.H., Ghofrani H.A., Oudiz R.J., Simonneau G., Safdar Z., Shapiro S., White R.J., Chan M., Beardsworth A., Frumkin L., Barst R.J. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.
29. Hatano M., Yao A., Kinugawa K., Hirata Y., Nagai R. Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan. Int Heart J 2011, 52:233-239.
30. Burgess G., Hoogkamer H., Collings L., Dingemanse J. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol 2008, 64:43-50.
31. Wharton J., Strange J.W., Moller G.M., Growcott E.J., Ren X., Franklyn A.P., Phillips S.C., Wilkins M.R. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005, 172:105-113.
32. Ghofrani H.A., Pepke-Zaba J., Barbera J.A., Channick R., Keogh A.M., Gomez-Sanchez M.A., Kneussl M., Grimminger F. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43:68S-72S.
33. Wilkins M.R., Wharton J., Grimminger F., Ghofrani H.A. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008, 32:198-209.
34. Hoeper M.M., Faulenbach C., Golpon H., Winkler J., Welte T., Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004, 24:1007-1010.
35. Gomberg-Maitland M., McLaughlin V., Gulati M., Rich S. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 2005, 96:1334-1336.
36. Benza R.L., Rayburn B.K., Tallaj J.A., Pamboukian S.V., Bourge R.C. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: Long-term efficacy and combination with bosentan. Chest 2008, 134:139-145.
37. Akagi S., Matsubara H., Miyaji K., Ikeda E., Dan K., Tokunaga N., Hisamatsu K., Munemasa M., Fujimoto Y., Ohe T. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circ J 2008, 72:1142-1146.
38. McLaughlin V.V., Oudiz R.J., Frost A., Tapson V.F., Murali S., Channick R.N., Badesch D.B., Barst R.J., Hsu H.H., Rubin L.J. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174:1257-1263.
39. Rich S., Pogoriler J., Husain A.N., Toth P.T., Gomberg-Maitland M., Archer S.L. Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest 2010, 138:1234-1239.
40. Simonneau G., Rubin L.J., Galie N., Barst R.J., Fleming T.R., Frost A.E., Engel P.J., Kramer M.R., Burgess G., Collings L., Cossons N., Sitbon O., Badesch D.B. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149:521-530.
41. Maki H., Yao A., Inaba T., Shiga T., Hatano M., Kinugawa K., Yamashita T., Aizawa T., Nagai R. Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension. Int Heart J 2011, 52:323-326.
42. Kemp K., Savale L., O'Callaghan D.S., Jais X., Montani D., Humbert M., Simonneau G., Sitbon O. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 2012, 31:150-158.
43. Ghofrani H.A., Morrell N.W., Hoeper M.M., Olschewski H., Peacock A.J., Barst R.J., Shapiro S., Golpon H., Toshner M., Grimminger F., Pascoe S. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010, 182:1171-1177.
44. Schermuly R.T., Dony E., Ghofrani H.A., Pullamsetti S., Savai R., Roth M., Sydykov A., Lai Y.J., Weissmann N., Seeger W., Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115:2811-2821.
45. Hatano M., Yao A., Shiga T., Kinugawa K., Hirata Y., Nagai R. Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension. Int Heart J 2010, 51:272-276.
46. Tamaki Z., Asano Y., Hatano M., Yao A., Kawashima T., Tomita M., Kinugawa K., Nagai R., Sato S. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. Mod Rheumatol 2012, 22:94-99.
47. Overbeek M.J., Boonstra A., Voskuyl A.E., Vonk M.C., Vonk-Noordegraaf A., van Berkel M.P., Mooi W.J., Dijkmans B.A., Hondema L.S., Smit E.F., Grunberg K. Platelet-derived growth factor receptor-beta and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study. Arthritis Res Ther 2011, 13:R61.
48. Stasch J.P., Becker E.M., Alonso-Alija C., Apeler H., Dembowsky K., Feurer A., Gerzer R., Minuth T., Perzborn E., Pleiss U., Schroder H., Schroeder W., Stahl E., Steinke W., Straub A., et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001, 410:212-215.
49. Schermuly R.T., Stasch J.P., Pullamsetti S.S., Middendorff R., Muller D., Schluter K.D., Dingendorf A., Hackemack S., Kolosionek E., Kaulen C., Dumitrascu R., Weissmann N., Mittendorf J., Klepetko W., Seeger W., et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008, 32:881-891.
50. Ghofrani H.A., Hoeper M.M., Halank M., Meyer F.J., Staehler G., Behr J., Ewert R., Weimann G., Grimminger F. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010, 36:792-799.
51. Simonneau G, Torbicki A, Hoeper MM, Delcroix M, Karlocai K, Galie N, Degano B, Bonderman D, Kurzyna M, Efficace M, Giorgino R, Lang IM. Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J, 2012; erj01375-2011.